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Background: Bickerstaff’s encephalitis (BE) is an acute post-infectious demyelinating disease with albuminocytological
dissociation. A chronic form has rarely been described previously.
Case presentation: A 44-year-old man was hospitalized for drowsiness, cognitive complaint limb weakness, ataxia
and sensory disturbance after diarrhea. Neuropsychological evaluation showed slowing, memory and executive
function impairment, while analysis of the CSF showed albuminocytological dissociation. Immunologic tests
showed positive anti-ganglioside antibodies (anti-GM1 IgM, anti-GD1a IgG and anti-GD1b IgM). Brain MRI was
normal but SPECT showed bilateral temporal and frontal hypoperfusion. Outcome under immunoglobulin
treatment (IVIG) was favorable with an initial improvement but was marked by worsening after a few weeks.
Consequently, the patient was treated with IVIG every 2 months due to the recurrence of symptoms after 6 weeks.
Conclusion: This case raises the question of the existence of a chronic form of BE with cognitive impairment, in the
same way as chronic inflammatory demyelinating polyneuropathy is considered to be a chronic form of Guillain–Barré
syndrome.
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In 1951, Bickerstaff and Cloake described an encephalitis
consisting in an association of ophthalmoplegia, ataxia
and consciousness disturbance following an acute infec-
tion [1-4]. This entity known Bickerstaff ’s encephalitis
(BE) is close to Guillain–Barré syndrome (GBS) and
Miller Fischer syndrome, with the presence of an
albumino-cytological dissociation in the cerebrospinal
fluid [2]. The etiology of BE is speculated to be similar
to that of GBS because of the existence of a prodromal
infection. Several studies have shown that anti-
ganglioside antibodies can be positive in BE [4-6]. The
course of BE is usually described as monophasic, with
only one acute episode. The prognosis depends on the* Correspondence: frederic.blanc@chru-strasbourg.fr
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unless otherwise stated.severity of consciousness disturbance, which can range
from drowsiness to coma. Treatment consists in intra-
venous corticosteroids, intravenous immunoglobulin
(IVIg) or plasmapheresis [5-7].
We report a case of a patient in whom the course was
chronic with cognitive impairment, suggesting the exist-
ence of a chronic form of BE.
Case presentation
A 44-year-old man, in whom the only antecedent was
lumbar disc herniation, had experienced various symp-
toms while on a visit to Senegal. The symptoms that ap-
peared one week after his arrival included high fever,
chills, drowsiness and not-bloody diarrhea. Two weeks
after his return in France, he experienced additional
symptoms: intense drowsiness with cognitive complaint,
leg weakness, asthenia, joint pain (elbows, wrists, knees)
and diffuse myalgia. Severe psychomotor slowing and
impaired concentration led him to consult a physician.
The patient was referred to a local hospital but no diag-
nosis was made at that time. After one year without al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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our tertiary center. He complained of drowsiness, cogni-
tive difficulties, but also mild diarrhea. Clinical examin-
ation revealed a deficit in all four extremities, deep
sensory impairment in the lower limbs, proprioceptive
ataxia, distal pain, diminished cognitive speed and atten-
tion deficit. He presented also with a vitiligo. The rest of
the physical examination was unremarkable: in particular,
tendon reflexes were present and symmetrical and there
were no abnormal eye movements. Neuropsychological
evaluation found a diminished speed of information pro-
cessing, short-term and working memory impairment and
attention and executive functioning disorders: the patient
had a “subcortical” cognitive impairment. Thus, we used
the BCcogSEP battery to evaluate cognitive functions [8].
BCcogSEP is the French modified version of the Brief
Repeatable Battery of Neuropsychological tests for Mul-
tiple Sclerosis (BRB-N) proposed by Rao and comprises
the 5 modified BRB-N tests: a Selective Reminding Test
(BCcog-SRT), a visuospatial memory test (10/36), the
Paced Auditory Serial Addition Test (PASAT), a verbal
fluency test, and the digit symbol substitution test of
the WAIS-R (DSST) [9]. Three tasks were added in order
to provide additional information about working mem-
ory and executive functions: the crossed tapping test, a
“Go-No-Go” test and the WAIS-R digit span subtest.
Among these 14 subtests, 11 were impaired, including
the three subtests of SRT, the immediate recall of 10/36,
the forward and backward digit span, the DSST, the
PASAT, the crossed tapping test and the semantic and
phonemic fluency tests.
Moreover, Free and Cued Selective Recall Reminding
Test (FCSRT) [10] for verbal episodic memory showed a
normal score of 16 out of 16 words for immediate recall
and scores of 6-9-9/16 (<5th percentile) for free recall
and 12-15-15/16 for total recall (i.e. within the normal
range), showing an improvement after cueing. In the vis-
ual object recognition memory test (DMS 48) [11] the
patient was deficient, with only 71% correct answers a
few minutes after presentation of the pictures, and 69%
correct answers one hour after. The Mini-Mental Status
Examination (MMSE) score was normal: 28 (recall 1/3).
The Rey-Osterrieth complex figure copy was normal
[12].
Brain MRI and electroencephalogram were normal
whereas SPECT showed bilateral temporal and frontal hy-
poperfusion (Figure 1). Somatosensory evoked potentials
(SEP) were abnormal in the left leg, with a discrete de-
layed cortical wave latency. The motor nerve conduction
study revealed a right carpal tunnel syndrome but found
no other abnormalities; in particular, there was no evi-
dence to suggest demyelination or axonal degeneration.
The CSF study showed a high protein level (0.80 g/l)
with a normal number of white and red cells, negativepolymerase chain reaction results for herpes simplex
virus, the absence of oligoclonal bands, and a negative
Lyme serology. These findings indicated the presence of
an albumino-cytological dissociation. Different infectious
causes has been researched in the blood but were negative:
HCV, HBV, HIV, anguillula, ascaris, trypanosoma, schis-
tosoma, fasciola hepatica, malaria, tropheryma whipplei,
blastocystis hominis. Stool parasitological examinations
were negative. Bacteriological examination of stool sam-
ples (after the third taking) revealed the presence of
Campylobacter jejuni. Anti-ganglioside antibodies were
positive (immunodot; anti-GM1 IgM: 1/2000, anti-GD1a
IgG: 1/2000, anti-GD1b IgM: 1/500, anti-GQ1b: negative).
BE was diagnosed and the patient was treated with IVIG
for 5 days. This led to an improvement in symptoms (i.e.
regression of limb weakness and pain, improvement in
cognitive impairment, particularly in terms of language
and memory).
Unfortunately, after 2 months, the patient relapsed with
the same clinical presentation. This led us to consider his
symptoms as chronic. Consequently, he received IVIG
treatment every 2 months, with a systematic recurrence of
symptoms after 6 weeks. An immunosuppressive drug,
mycophenolate mofetil, was tested, but was poorly to-
lerated and the patient was switched to azathioprine
100 mg/day that was also stopped because it did not
permit to diminish the frequency of IVIG. For the past
4 years, the time between 2 courses of IVIG has been
about 3 months. The patient is now stabilized with this
treatment but it is impossible to stop IVIG permanently
because a relapse occurs a few weeks after IVIG with-
drawal. He probably presented a chronic progressive
form of BE because relapses are not totally stopped des-
pite the treatment.
Discussion
In our patient, the diagnosis of chronic BE was based on
the following: sensory and motor disturbances in all four
limbs, vigilance and cognitive disorders, CSF albuminocy-
tological dissociation, positive anti-ganglioside antibodies,
and presence of C. jejuni in stool samples. Chronic form
of BE is suspected since the patient worsened before IVIG
treatment and since every stop of the treatment pulls a
worsening a few weeks later.
The classic presentation of BE, combining classic symp-
toms such as consciousness disturbance, ophthalmoplegia
or ataxia, may be incomplete and/or associated with other
neurological signs (Babinski’s sign, sensory disturbance,
facial and limb weakness) [13].
The albuminocytological dissociation typically appears
after the second week [14]. When anti-ganglioside anti-
bodies are positive, they can be of various types: IgG
antibody to GQ1b is the most frequent [6,13-16]. Accord-
ing to the study of Odaka et al. including 62 patients, [14],
Figure 1 SPECT of the patient with chronic BE showing bilateral temporal and frontal hypoperfusion.
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thus negative in 34% of cases-. It seems that antibodies to
GD1a, GD1b and GM1 are more often positive when BE
is associated with limb weakness as in our case [14]. Anti-
gangliosides IgM antibodies (such as two antibodies for
our patient) are usually associated with chronic forms of
neuropathies [17,18].
C. jejuni is frequently involved in BE, as in our case
where the primary symptom was diarrhea [13,14,16,19,20].
Interestingly, our patient had a chronic diarrhea and
developed a chronic form of BE. Recently, animal
models of infection with campylobacter jejuni showed
that long-term C. jejuni infection not only induced
intestinal but also long term extra-intestinal immune
responses in organs [21]. Indeed, mechanisms for in-
duced autoimmunity by infection include the activationAcute 
GBS 
(AIDP)
BE
Figure 2 Plan of the supposed place of chronic BE within the acute aof autoreactive cells by an encounter with a pathogen
epitope [22]. Molecular mimicry may trigger autoimmune
tissue damage and induce acute inflammation, as in
the case of GBS and Miller Fisher syndrome [23]. This
acute form of inflammation could evolve into a chronic
form [24].
The electroencephalogram is reported to be abnormal,
showing slow activity in the theta or delta range in 57–
70% of cases [13,14]. Electromyographic evidence of de-
myelination or axonal degeneration is found in half of
all cases [13,14]. These two examinations were normal
in our patient but they were performed more than a year
after the onset of the disease.
Brain MRI is reported to be normal in 75% to 90% of
patients with BE, as was the case in our patient [4,25-27].
Hyperintensities in the pons, thalamus, medulla oblongataChronic 
CIDP
Chronic
BE?
nd chronic inflammatory pathologies of the nervous system.
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sometimes observed. This vasogenic edema could be re-
versible and not visible in MRI.
Neuropsychological tests were not described in previ-
ous studies on BE. In our patient, the cognitive profile
was fronto-temporal with slowing, which corresponded
to the SPECT abnormalities. SPECT could be abnormal
in BE while MRI is normal. Indeed, in a recent case re-
port of BE with normal MRI, SPECT showed hypoperfu-
sion of the whole cerebral hemispheres and basal ganglia
with relative sparing of the thalami and of the brainstem
[28]. SPECT might therefore be a diagnostic tool in BE
despite a lack of specificity.
Immunotherapy (IVIG or plasmapheresis) is usually the
standard treatment for BE [5,7,29]. In our patient, IVIG
dependence suggests a progression to chronic auto-
immune encephalitis with persistent inflammatory activity.
BE is considered to be a monophasic disease. Only rarely
is BE documented to relapse [30,31]. A patient, presented
with recurrent drowsiness, unsteady gait, diplopia, has
been described as recurrent Fisher-Bickerstaff syndrome
by Dong et al. [30]. Sharma et al. described a second case
with recurrent BE with overlapping features of GBS and
Miller-Fisher syndrome without anti-gangliosides [31].
Nonetheless, our case was different because he had rather
a progressive chronic form without total relapses. Indeed,
if we stopped the IVIG, he deteriorated.
Conclusions
Our case suggests the existence of a possible chronic BE with
anti-gangliosides, underpinned by mechanisms of molecular
mimicry, secondary to infection, and then evolving on its
own account like other neurological autoimmune diseases.
Also, there is a parallelism and/or a continuum between
some neurological inflammatory diseases: for example,
between GBS and chronic inflammatory demyelinating
polyneuropathy neuropathy (CIDP) (Figure 2). In conclu-
sion, this case could correspond to a chronic form of BE
with cognitive impairment.
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